(Q33419097)

26 July 2017

Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma (English)

1 reference

metastatic renal cell carcinoma

26 July 2017

phase I clinical trial

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

Matthew T Campbell

1

1 reference

26 July 2017

Randall E Millikan

2

1 reference

26 July 2017

Emre Altinmakas

3

1 reference

26 July 2017

Lianchun Xiao

4

1 reference

26 July 2017

Sin Jen Wen

5

1 reference

26 July 2017

Arlene O Siefker-Radtke

6

1 reference

26 July 2017

Ana Aparicio

7

1 reference

26 July 2017

Paul G Corn

8

1 reference

26 July 2017

Nizar M Tannir

9

1 reference

26 July 2017

language of work or name

English

0 references

publication date

24 October 2014

1 reference

Clinical Genitourinary Cancer

26 July 2017

1 reference

26 July 2017

13

1 reference

26 July 2017

3

1 reference

26 July 2017

218-224

1 reference

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Temsirolimus, an inhibitor of mammalian target of rapamycin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Sunitinib: from rational design to clinical efficacy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Sunitinib in patients with metastatic renal cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

Dose‐Finding with Two Agents in Phase I Oncology Trials

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4991027

10.1016/J.CLGC.2014.10.004

31 October 2018

Identifiers

DOI

1 reference

release_zf36mfgjt5daveimze2bljadfe

26 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zf36mfgjt5daveimze2bljadfe

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMCID

4991027

1 reference

26 July 2017

1 reference